Advertisement
UK markets close in 8 hours 29 minutes

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.24 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1651
    -0.0009 (-0.07%)
     

  • GBP/USD

    1.2544
    -0.0020 (-0.16%)
     

  • Bitcoin GBP

    50,727.90
    -483.45 (-0.94%)
     

  • CMC Crypto 200

    1,367.69
    +2.56 (+0.19%)
     

  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     

  • DOW

    38,852.27
    +176.59 (+0.46%)
     

  • CRUDE OIL

    78.58
    +0.10 (+0.13%)
     

  • GOLD FUTURES

    2,328.40
    -2.80 (-0.12%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,464.34
    -113.96 (-0.61%)
     

  • DAX

    18,175.21
    +173.61 (+0.96%)
     

  • CAC 40

    7,996.64
    +39.07 (+0.49%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

Gilead Sciences Stock: How Much Upside Do Analysts Expect?

Kenneth Smith
Updated
Gilead Sciences Stock: How Much Upside Do Analysts Expect?

Gilead Sciences (GILD) is a research-based biopharmaceutical company focused on discovering, developing, and bringing to market innovative medicines for life-threatening diseases. Gilead released its first-quarter earnings on May 4. Of the 26 analysts covering Gilead Sciences stock in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.2 with a target price of $85.81, which implies an upside potential of 27.2% over its closing price of $66.99 on May 15.

Continue reading